[半身照射。78例治疗中的姑息疗效及反应预测因素]

[Half-body irradiation. Palliative efficacy and predictive factors of response in 78 procedures].

作者信息

Algara M, Valls A, Ruiz V, Jaume M, Lacruz M, Foro P

机构信息

Servicio de Radioterapia, Hospital de la Esperanza, Barcelona.

出版信息

Med Clin (Barc). 1994 Jun 18;103(3):85-8.

PMID:8065222

Abstract

BACKGROUND

Assessment of palliative effect of hemibody irradiation (HBI) and response-related factors.

METHODS

Analysis of prospective collected data of 78 procedures on 71 patients with multiple symptomatic bone metastases, treated with 6 Gy (upper half-body) or 8 Gy (lower half-body) HBI in single fraction. Clinical improvement was quantified by self-evaluation on a visual analogic scale (SVAS) before HBI, and at 24, 48 and 72 hours, at 7 days, and at each monthly control until patient's death. Univariate analysis included: sex, Karnofsky's index, tumor origin, histology, HBI dose, and SVAS before treatment. For statistical purposes the significance level was 0.05.

RESULTS

Complete (37.5%) or partial responses were observed in 72/78 (92.3%) procedures, 80% appearing during the first 72 hours. Difference between mean SVAS, before and after treatment (7.7 +/- 1.5 vs 2.8 +/- 2.5), was statistically significant (p < 0.001). A mean response duration of 101 days over a mean overall survival of 141 days implies the 70% of expected patient's life span. Any analyzed prognostic factor does not correlate significantly with HBI response.

CONCLUSIONS

HBI is a powerful palliative treatment in patients with multiple symptomatic bone metastasis.

摘要

背景

半身照射（HBI）的姑息治疗效果及反应相关因素评估。

方法

对71例有多处症状性骨转移的患者进行的78次治疗程序的前瞻性收集数据进行分析，单次分割给予6 Gy（上半身）或8 Gy（下半身）的HBI。临床改善通过HBI前以及24、48和72小时、7天以及直至患者死亡的每月每次复查时的视觉模拟量表自我评估（SVAS）进行量化。单因素分析包括：性别、卡诺夫斯基指数、肿瘤起源、组织学、HBI剂量以及治疗前的SVAS。为了统计目的，显著性水平为0.05。

结果

72/78（92.3%）次治疗程序观察到完全缓解（37.5%）或部分缓解，80%在最初72小时内出现。治疗前后平均SVAS的差异（7.7±1.5对2.8±2.5）具有统计学意义（p<0.001）。平均缓解持续时间为101天，平均总生存期为141天，意味着预期患者寿命的70%。任何分析的预后因素与HBI反应均无显著相关性。